DeCure for Generalized epilepsy with febrile seizures plus
DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for generalized epilepsy with febrile seizures plus — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGeneralized epilepsy with febrile seizures plus maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for generalized epilepsy with febrile seizures plus is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
sodium voltage-gated channel beta subunit 1 (SCN1B) — SCN1B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7W9K · 2.2 Å · ligand O-[(R)-{[(2R)-2,3-bis(octadecanoyloxy)propyl]oxy}(hydroxy)phosphoryl]-L-serine (P5S). Experimental structure, not a prediction.
What the evidence adds up to
In a 2009 Italian task force guideline, febrile seizures are defined as short (<15 min) generalised seizures in children aged 6 months to 5 years, occurring during a febrile illness without acute nervous system disease, with no prior afebrile seizures. The authors stress that most cases have a benign prognosis. Both continuous and intermittent anticonvulsant therapy can prevent single febrile seizures, but side effects may outweigh benefits, and treatment is indicated only in very selected patients. A 2000 review agrees that daily prophylaxis should never be used routinely in simple febrile seizures, and only in highly selected cases if at all. Intermittent diazepam at times of fever may or may not reduce recurrence rate, but does not appear to improve long-term outcome compared with short-term seizure control. There is no evidence that treating simple febrile seizures prevents the rare cases of later epilepsy, and many children with complex febrile seizures have a benign long-term outcome even without treatment.
A 1998 review argues that the relationship between febrile seizures and later epilepsy is frequently genetic, and that there are syndrome-specific genes for febrile seizures. A 2007 family study of 51 members across four generations found 13 affected individuals, all with febrile seizures, five also with childhood absence epilepsy, and one with temporal lobe epilepsy. After excluding known loci, a genome-wide search mapped a new locus for febrile seizures on chromosome 3p. A possible modifier gene on chromosome 18p could not be excluded, and all patients with epilepsy shared a common haplotype at this locus in addition to the 3p haplotype. The authors conclude that epilepsy in association with febrile seizures might result from an interaction between at least two genes.
A 2009 study of 155 out-patients with complex partial seizures found that 14 (9%) had a history of febrile seizures. Twelve of these had prolonged or recurrent febrile seizures, convulsive status epilepticus, or a transient postictal neurological deficit. Febrile seizures in this group were associated with perinatal abnormalities, earlier onset of epilepsy, and poor seizure control. The authors state that recurrent febrile seizures or those with complicating features are associated with an unfavourable therapeutic outcome in adult patients with complex partial seizures. What remains missing is a clear, evidence-based stratification that identifies which children with febrile seizures will later develop epilepsy, and prospective trials testing whether any intervention alters that long-term risk rather than merely suppressing acute seizures.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Epilepsia · 2009 · 171 citations
Recommendations for the management of “febrile seizures” Ad hoc Task Force of LICE Guidelines Commission
AbstractFebrile seizures are the most common seizure disorder in childhood, affecting 2-5% of children. Simple febrile seizure is defined as a short (<15 min) generalized seizure, not recurring within 24 h, that occurs during a febrile illness not resulting from an acute disease of the nervous system in a child aged between 6 months and 5 years, with no neurologic deficits and no previous afebrile seizures. These recommendations address the instructions for management of the first febrile seizures, giving criteria for hospital admission, diagnosis, differential diagnosis, and treatment of a prolonged seizure. The authors stressed the benign prognosis of the majority of cases and the risk factors for recurrence of febrile seizures and appearance of epilepsy later on. Both continuous and intermittent anticonvulsant therapy are efficacious in preventing single febrile seizures, but side effects may be so important to overcome the benefits. These treatments are indicated in very selected patients.
AbstractRecent epidemiologic data indicate that the vast majority of children with febrile seizures have a normal longterm outcome. A precise knowledge of the short- and long-term outcome with or without treatment, and short- and long-term side effects is an important prerequisite for assessing the various treatment strategies. We focus on the impact of short-term or prophylactic treatment on the short- and long-term outcome of various types of febrile seizures. There is universal agreement that daily prophylaxis with antiepileptic agents should never be used routinely in simple febrile seizures, but only in highly selected cases, if at all. Intermittent diazepam (DZP) prophylaxis at times of fever may or may not reduce the recurrence rate, but it does not appear to improve the long-term outcome as compared with short-term seizure control. The treatment may be used to reduce the recurrence rate for a small arbitrarily defined group with multiple simple febrile seizures, complex febrile seizures, especially focal, prolonged or both, febrile status, and when parental anxiety is severe. However, there is no evidence that treatment of simple febrile seizures can prevent the rare cases of later epilepsy, and many children with complex febrile seizures have a benign long-term outcome, even without treatment. Many prefer a "wait and see" policy. An attractive alternative is to treat new febrile seizures with rectal DZP in solution at seizure onset, given by the parents at home to prevent febrile status. Newer, less well documented short-term strategies include nasal, oral, or rectal administration of other benzodiazepines. Short-term seizure control of febrile status and careful parental counseling are the two most important targets of treatment.
Current Opinion in Neurology · 1998 · 67 citations
Febrile seizures: genetics and relationship to other epilepsy syndromes
AbstractThe relationship between febrile seizures and epilepsy has long been debated. We argue that there is some specificity to the types of epilepsy that follow febrile seizures, rather than febrile seizures being a nonspecific marker of a lowered seizure threshold. The relationship between febrile seizures and later epilepsy is frequently genetic. Recent clinical and molecular genetic studies suggest that there are a number of syndrome-specific genes for febrile seizures.
New locus for febrile seizures with absence epilepsy on 3p and a possible modifier gene on 18p
AbstractOBJECTIVE: To report a clinical and genetic study of a large family with febrile seizures (FS) and childhood absence epilepsy (CAE). METHODS: This family was identified through a French campaign for familial epilepsies. It spans four generations and consists of 51 members, 13 of whom were affected. The medical history of all members was obtained by personal information and by consulting the medical files of affected members. All family members gave written consent to participate in the study. RESULTS: All affected members presented FS, with CAE in five and temporal lobe epilepsy (TLE) in one. FS stopped before age 6 years in all but one patient. FS were simple, except in one patient who had a long-lasting complex FS at 8 months of age. He later presented pharmacoresistant TLE and left hippocampal sclerosis was visible on brain MRI. Patients presenting CAE had recorded absences and characteristic EEGs with 3 Hz spike waves. After exclusion of reported loci for FS and generalized epilepsy with FS plus, a genome-wide search allowed us to map a new locus for FS on 3p. We could not exclude another genomic segment on chromosome 18p and all patients presenting epilepsy (CAE and TLE) shared a common haplotype at this locus in addition to the haplotype on 3p. CONCLUSION: These findings emphasize the genetic heterogeneity of febrile seizures. Furthermore, epilepsy in association with febrile seizures might result in this family from an interaction between at least two genes: the gene on 3p and a possible modifier gene on 18p.
Febrile seizures in patients with complex partial seizures
AbstractFebrile seizures occurred in 14 of 155 (9%) out-patients with complex partial seizures. Twelve patients had prolonged or recurrent febrile seizures, convulsive status epilepticus or a transient postictal neurological deficit. Febrile seizures were associated with perinatal abnormalities, an earlier onset of epilepsy and with a poor seizure control. Recurrent febrile seizures or those with complicating features are associated with an unfavourable therapeutic outcome in adult patients with complex partial seizures.
Cleveland Clinic Journal of Medicine · 1984 · 1 citations
Febrile convulsions: a new look at an old problem
AbstractFebrile convulsions commonly occur in children and may recur in approximately 25% to 50% of patients, but intelligence and learning do not appear to be influenced even after frequent recurrences. The risk of future epilepsy is low in most patients; however, a small group of high-risk children can be identified by prior abnormal neurologic status, atypical seizures, or a family history which reveals a close relative with epilepsy. Chronic phenobarbital prophylaxis can protect patients against recurrent febrile convulsions, but the effects of such treatment on the later development of epilepsy are not known. Most children with febrile convulsions need not be treated with anticonvulsants.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
